The MDS Beacon™

Researchers have published results of a clinical study examining a five-day intravenous (IV) dosing regimen for Vidaza (azacitidine), a common treatment for myelodysplastic syndromes (MDS).

The researchers, based at Washington University in St. Louis, find that a five-day IV regimen yielded response rates and response durations similar to those reported for the standard seven-day subcutaneous Vidaza dosing regimen. At the same time, overall survival times for the five-day regimen were lower than observed in studies using the standard regimen.

Vidaza is typically administered by two or three subcutaneous injections each…